期刊文献+

调脂新药Evolocumab的临床评价

下载PDF
导出
摘要 Evolocumab是一种抑制前蛋白转化酶枯草溶菌素9(PCSK9)的全人源单克隆抗体,由美国安进公司开发,目前正在进行多项3期临床研究,用于高脂血症的治疗。临床研究显示其降低低密度脂蛋白胆固醇(LDL-C)幅度达40%~80%,安全且耐受性好,为降脂治疗带来了新的药物选择。
出处 《中国处方药》 2014年第9期143-144,共2页 Journal of China Prescription Drug
  • 相关文献

参考文献13

  • 1Verma, Focus on Potential Role of Recombinant AntiPCSK9Monoclonal Antibodies.Rev Cardiovasc Med,2014,15 (2) :86-101.
  • 2Zhao S.Prevalence of dyslipidaemia in patients treated withlipidlowering agents in China Results of DYSIS. Atherosclerosis, 2014,235(2):463-469.
  • 3Stock.Improving the care of high-risk patients:potential of PCSK9.Atherosclerosis,2014,232 (2) :420-422.
  • 4Sahebkar.New LDL-cholesterol lowering therapies : pharmacology,clinical trials. Clin Ther, 2013,35 (8) :1082-1098.
  • 5Cicero.Efficacy and safety profile of AMG145 an inhibitor of pcsk9.Expert Opin Biol Ther> 2014,14 (6) :863-868.
  • 6BlomD.A52-week trial of AMG145 in hyperlipidemia.N Engl JMed,2014,370 (19) :1809-1819.
  • 7KorenM.Anti-PCSK9 monotherapy for hypercholesterolemia:MENDEL-2 J Am Coll Cardiol, 2014,63 (23):2531-2540.
  • 8ACC2014.Report of RUTERFORD-2 Trial Of AMG145 In PatientsWith Heterozygous FH at ACC2014,2014.
  • 9Robinson.Effect of AMG145 or ezetimibe added to statin therapy onLDL-C lowering: LAPLACE-2. JAMA, 2014.311 (18) :1870-1882.
  • 10StroesE.Anti-PCSK9 antibody effectively lowers cholesterol inpatients with statin intolerance: GAUSS-2.J Am Coll Cardiol,2014,63(23) -.2541-2548.

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部